Trending
Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024
We’re proud to have been named a Leader in the Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Report. Everest Group classified ...
Should Pharmaceutical Incentive Compensation Plans Cap At-Risk Sales Rep Compensation?
This white paper looks at a simple but important research question – why do pharma companies have incentive compensation (IC) plans that cap their at-risk sales rep compensation? This paper provides reasons why such caps are not justified on both theoretical and empirical grounds, notes counterarguments to those who argue for IC caps, and offers two typical case studies that reveal both negative ...
The Evidence Supporting Sales Rep Access Restrictions To Physicians – “Where’s The Beef?”
The last 10-15 years have seen an explosion of articles in major health policy and medical journals advocating severely restricting or banning biopharmaceutical sales rep access to physicians in all settings. With very few exceptions, the prevailing narrative has gone unchallenged. This paper provides a more in-depth and balanced look into the evidence supporting the current narrative and ...